Nuformix plc (LON:NFX – Get Free Report)’s share price dropped 10.7% during trading on Monday. The stock traded as low as GBX 0.07 and last traded at GBX 0.07. Approximately 40,185,859 shares traded hands during trading, an increase of 43% from the average session volume of 28,199,766 shares. The stock had previously closed at GBX 0.08.
Nuformix Trading Down 10.7%
The stock has a market capitalization of £1.96 million, a price-to-earnings ratio of -2.56 and a beta of 1.53. The firm has a 50-day moving average of GBX 0.13 and a 200 day moving average of GBX 0.17.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Recommended Stories
- Five stocks we like better than Nuformix
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
